| 摘要 |
The invention is based on the surprising finding that proteins regulated by excessive EGFR signalling in the liver may be used as biomarkers in the diagnosis, prognosis and/or monitoring of treatment of diseases, including liver cell dysplasia or hepatocellular carcinoma (HCC), wherein the protein is selected from a first group consisting of Arginase type II, 4931406C07Rik (Ester hydrolase C11orf54 homolog), Akr1c12 protein, Alanyl-tRNA synthetase, Aldo-keto reductase family 1 member C14, Aldo-keto reductase family 1 member C6, Aldolase 3, Alpha glucosidase 2, Beta 5-tubulin, Cai protein (Pdia4), cDNA sequence BC021917 (dihydroxyacetone kinase 2 homolog), Farnesyl diphosphate synthetase, Fatty acid binding protein 5 epidermal, Inosine triphosphatase, Interleukin 25, Kininogen 1, LIM and SH3 protein 1, Major vault protein, Nucbl protein, Poly(rC) binding protein 2; heterogeneous nuclear ribonucleoprotein X, Psmd11 protein, RIKEN cDNA 2410004H02, Rps12 protein, Sarsl protein, Sorcin, T43799 proteasome protein p45/SUG [imported], Uap1 l1 protein, v-crk sarcoma virus CT10 oncogene homolog, and 170 kDa glucose regulated protein GRP170 precursor, or from a second group consisting of 2-hydroxyphytanoyl-CoA lyase, Branched chain ketoacid dehydrogenase E1 alpha polypeptide, Butyryl Coenzyme A synthetase 1,Dhdh protein, Diacetyl/L-xylulose reductase, Dmgdh protein (Dimethylglycine dehydrogenase, mitochondrial), Enoyl coenzyme A hydratase 1 peroxisomal, Hypothetical protein LOC68347, Lysophospholipase 1, Mitochondrial acyl-CoA thioesterase 1, PREDICTED: agmatine ureohydrolase (agmatinase), RIKEN cDNA 1810013B01 (abhydrolase domain containing 14b ), and Serpinbla protein. Based on this finding novel biomarkers and molecules binding to said biomarkers, compositions and a kit, as well as methods for the diagnosis, prognosis and/or monitoring of treatment of dysplasia and cancer patients, in particular of liver cell dysplasia and hepatocellular carcinoma (HCC) patients are provided according to the invention. |
